Document Detail


Matrix metalloproteinase inhibition protects CyPD knockout mice independently of RISK/mPTP signalling: a parallel pathway to protection.
MedLine Citation:
PMID:  23361433     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The mitochondrial permeability transition pore (mPTP) is widely accepted as an end-effector mechanism of conditioning protection against injurious ischaemia/reperfusion. However, death can be initiated in cells without pre-requisite mPTP opening, implicating alternate targets for ischaemia/reperfusion injury amelioration. Matrix metalloproteinases (MMP) are known to activate extrinsic apoptotic cascades and therefore we hypothesised that MMP activity represents an mPTP-independent target for augmented attenuation of ischaemia/reperfusion injury. In ex vivo and in vivo mouse hearts, we investigated whether the MMP inhibitor, ilomastat (0.25 μmol/l), administered upon reperfusion could engender protection in the absence of cyclophilin-D (CyPD), a modulator of mPTP opening, against injurious ischaemia/reperfusion. Ilomastat attenuated infarct size in wild-type (WT) animals [37 ± 2.8 to 22 ± 4.3 %, equivalent to ischaemic postconditioning (iPostC), used as positive control, 27 ± 2.1 %, p < 0.05]. Control CyPD knockout (KO) hearts had smaller infarcts than control WT (28 ± 4.2 %) and iPostC failed to confer additional protection, yet ilomastat significantly attenuated infarct size in KO hearts (11 ± 3.0 %, p < 0.001), and similar protection was also seen in isolated cardiomyocytes. Moreover, ilomastat, unlike the cyclophilin inhibitor cyclosporine-A, had no impact upon reactive oxygen species-mediated mPTP opening. While MMP inhibition was associated with increased Akt and ERK phosphorylation, neither Wortmannin nor PD98059 abrogated ilomastat-mediated protection. We demonstrate that MMP inhibition is cardioprotective, independent of Akt/ERK/CyPD/mPTP activity and is additive to the protection observed following inhibition of mPTP opening, indicative of a parallel pathway to protection in ischaemic/reperfused heart that may have clinical applicability in attenuating injury in acute coronary syndromes and deserve further investigation.
Authors:
Robert M Bell; Suma P Kunuthur; Cara Hendry; Damian Bruce-Hickman; Sean Davidson; Derek M Yellon
Related Documents :
23052973 - Cardiac magnetic resonance imaging of rapid vcam-1 up-regulation in myocardial ischemia...
19761983 - Increasing benefit from revascularization is associated with increasing amounts of myoc...
16251233 - Prognostic value of systolic mitral annular velocity measured with doppler tissue imagi...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2013-01-30
Journal Detail:
Title:  Basic research in cardiology     Volume:  108     ISSN:  1435-1803     ISO Abbreviation:  Basic Res. Cardiol.     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-01-30     Completed Date:  2013-07-18     Revised Date:  2014-08-20    
Medline Journal Info:
Nlm Unique ID:  0360342     Medline TA:  Basic Res Cardiol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  331     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Blotting, Western
Cyclophilins / physiology*
Extracellular Signal-Regulated MAP Kinases / metabolism*
Indoles / therapeutic use*
Male
Matrix Metalloproteinase Inhibitors / therapeutic use*
Mice
Mice, Inbred C57BL
Mice, Knockout
Mitochondrial Membrane Transport Proteins / metabolism*
Myocardial Infarction / metabolism,  prevention & control*
Myocardial Reperfusion Injury / metabolism,  prevention & control*
Myocytes, Cardiac / metabolism
Phosphorylation
Proto-Oncogene Proteins c-akt / metabolism*
Signal Transduction / drug effects
Grant Support
ID/Acronym/Agency:
PG/09/106/28142//British Heart Foundation; RG/08/015/26411//British Heart Foundation
Chemical
Reg. No./Substance:
0/Indoles; 0/Matrix Metalloproteinase Inhibitors; 0/Mitochondrial Membrane Transport Proteins; 0/mitochondrial permeability transition pore; EC 2.7.11.1/Proto-Oncogene Proteins c-akt; EC 2.7.11.24/Extracellular Signal-Regulated MAP Kinases; EC 5.2.1.-/Cyclophilins; EC 5.2.1.8/cyclophilin D; I0403ML141/ilomastat

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Large balloon dilation for the treatment of recurrent bile duct stones prevents short-term recurrenc...
Next Document:  Efficacy of herpes virus helicase-primase inhibitor, ASP2151, for treating herpes simplex keratitis ...